References
- Warren MP. Vaginal progesterone and the vaginal first-pass effect. Climacteric 2018;21:355–7
- Di Renzo GC. Concerns about the review of vaginal progesterone and the vaginal first-pass effect. Climacteric 2018;21
- Warren MP, Biller BM, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol 1999;180:42–8
- Bulletti C, de Ziegler D, Flamigni C, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997;12:1073–9
- Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol 1997;90:396–401
- Effects of Estrogen Or Estrogen/Progestin Regimens On Heart Disease Risk Factors In Postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199–208
- Zava DT, Groves MN, Stancyk FZ. Percutaneous absorption of progesterone. Maturitas 2014;77:91–2
- Ruan X, Mueck AO. Systemic progesterone therapy–oral, vaginal, injections and even transdermal? Maturitas 2014;79:248–55